THE VANGUARD NETWORK

2021 Forum for Healthcare and Life Sciences Leaders

DAY 1 - NOV 17 NOON TO 5 PM ET

Welcome and Introductions

Session 1: The New Transformation Agendas

Michelle McMurry-Heath - President & CEO, BIO Ambar Boodhoo - Partner, Ernst & Young Ray Jordan - Communications & Public Affairs Consultant

> "Transformation" is a term often used in the Life Sciences and Healthcare sectors -but what does it really mean now -- for C-Suite leaders and the businesses they run?

Rapidly changing industries are often fertile ground for mergers and acquisitions. But is creating and investing in collaborations and deep partnerships the key to creating transformative growth?

Break

Session 2: Are Healthcare and Life Sciences really social impact enterprises?

Cal Roberts - CEO, Lighthouse Guild Carolyn Morgan - President, Precision Health

The success of the COVID-19 vaccines has changed the narrative in our sector, away from the cost of medications to the societal benefit of our products.

Should we see ourselves as social impact enterprises? Will we need to demonstrate how and how much to governments and investors such as Blackstone? What are the expectations of our stakeholders about this?

Peer discussion

Session 3: New Value: Where will it be created, and how?

Eric Dube - President & CEO, Travere Therapeutics Cameron Durrant - Chairman & CEO, Humanigen Kathy Ku - Chief Licensing Advisor, Wilson Sonsini

> Valuations of biopharma companies conventionally have been based on their pipeline and marketed products. But is there equal value in elements such as patient engagement capabilities? And what will be the role of partnerships and collaborations?

> Are we seeing a decisive transformational shift by which innovations come from agile small companies, which are then developed and marked by global giants? What impact will the unprecedented speed of COVID-19 vaccine development have on other areas of biopharma?

Small group workshop